BLASUBCUTANEOUSINJECTABLE
Approved
May 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
STARJEMZA (ustekinumab-hmny) by Bio-Thera Solutions is interleukin-12 antagonists [moa]. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STARJEMZA (ustekinumab-HMNY) is a monoclonal antibody antagonist of interleukin-12, a key cytokine driver of immune-mediated inflammation. This is a biosimilar or follow-on biologic referencing the IL-12 pathway, approved via BLA for subcutaneous injection. The drug targets patients with IL-12-driven inflammatory and autoimmune conditions.
Launch
Early-stage launch with low linked job activity signals a small initial team; expect growth trajectory dependent on clinical adoption and reimbursement.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Bio-Thera Solutions is hiring 1 role related to this product
Worked on STARJEMZA at Bio-Thera Solutions? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.